Cargando…
Polygenic Risk Scores and the Need for Pharmacotherapy in Neonatal Abstinence Syndrome
OBJECTIVES: To identify genetic variants associated with NAS through a Genome Wide Association Study (GWAS) and estimate a Polygenic Risk Score (PRS) model for NAS. DESIGN: A prospective case-control study included 476 in-utero opioid-exposed term neonates. A GWAS of 1000 Genomes-imputed genotypes w...
Autores principales: | Bibi, Shawana, Gaddis, Nathan, Johnson, Eric O., Lester, Barry M., Kraft, Walter, Singh, Rachana, Terrin, Norma, Adeniyi-Jones, Susan, Davis, Jonathan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931940/ https://www.ncbi.nlm.nih.gov/pubmed/35974158 http://dx.doi.org/10.1038/s41390-022-02243-0 |
Ejemplares similares
-
59473 Clinical and demographic predictors of the need for pharmacotherapy in Neonatal Abstinence Syndrome (NAS)
por: Bibi, Shawana, et al.
Publicado: (2021) -
Association of a Simplified Finnegan Neonatal Abstinence Scoring Tool With the Need for Pharmacologic Treatment for Neonatal Abstinence Syndrome
por: Devlin, Lori A., et al.
Publicado: (2020) -
Development of an Abbreviated Symptom Score for the Neonatal Abstinence Syndrome
por: Chervoneva, I, et al.
Publicado: (2020) -
A review of the genomics of neonatal abstinence syndrome
por: Yen, Elizabeth, et al.
Publicado: (2023) -
Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone‐exposed neonates
por: Taleghani, Afshin A., et al.
Publicado: (2019)